Research on the drug has shown that it is more effective in controlling blood sugar and leads to greater weight loss compared to type 2 diabetes medications (semaglutide) currently available for prescription."Therezipatid" is derived from the glucose-dependent insulin peptide, which stimulates the release of insulin, but what distinguishes "terzipatid" is that it binds to the receptors of another hormone that also releases insulin, and this makes terzipatide the first "dual-hormone stimulator".The two hormones act on the pancreas to increase the production of the hormone insulin, This lowers blood glucose. It also slows down the speed of gastric emptying, making us feel full for longer. When combined, all of these elements have significant benefits in lowering blood sugar levels, and these effects have also been shown to lead to weight loss.The effects of the two hormones produced by our body naturally last only about two minutes. But terzibatide modifies the structure of these hormones so that they break down slowly and have a longer lasting effect (lasting about five days). A separate year-long study found that 15 mg of terzipatide was as effective at controlling blood glucose levels as insulin. Research shows that those who took terzipatide for type 2 diabetes lost an average of 8.5-13% of their body weight, while those who took semaglutide lost about 7%, according to a study published in the journal Science Alert.About 80-90% of people with type 2 diabetes are overweight or obese, and overweight, especially the weight carried around the medium, can lead to reduced insulin effectiveness and lower production of insulin. Use Theresipatide safely along with other diabetes medications (such as metformin) if diabetes control goals are not met.